A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School and Karolinska Institutet presents very promising results for the treatment of the cancer form multiple myeloma.
The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.
The journal Blood has published a new study on a drug candidate for multiple myeloma, a form of cancer that affects about one per cent of all tumour patients, with some 600 people a year developing the disease in Sweden. Multiple myeloma is a life-threatening disease and there is a dire medical need for new therapies, especially for the patients whose tumour cells have become resistant to the conventional drugs.
“The discovery that our substance works on multiple myeloma cells resistant to conventional therapy is very promising for the future, says Professor Stig Linder at Karolinska Institutet’s Department of Oncology-Pathology. “We’re now very hopeful that we and our colleagues at Harvard Medical School will be able to develop an effective treatment.”
The study demonstrates that the drug candidate, called VLX1570, inhibits tumour growth and prolongs survival in preclinical multiple myeloma models. The exact mechanism of action of the substance was identified earlier at Karolinska Institutet (Nature Medicine, 2011). Put simply, the tumour cells can be said to be more sensitive than normal cells to disruption to the machinery that breaks down defective proteins. When this machinery is blocked, it triggers apoptosis (programmed cell death) in the tumour cells.
“We show that the drug candidate kills multiple myeloma cells from cancer patients,” says Professor Linder. “The substance is also effective against myeloma cells that have developed a resistance to the clinically used drug bortezomib.”
Dr Dharminder Chauhan at Harvard Medical School says that the mechanism of action is very interesting as regards the development of new cancer drugs and adds, “We’re delighted to be able to study the therapeutic potential of this new drug candidate in clinical studies. We hope that the joint research we’re doing will lead to improved cancer treatments.”
The study also found that the new substance could be combined synergistically with other cancer therapies. Karolinska Institutet and Harvard Medical School are due to launch a large-scale clinical study next year in association with drug discovery company Vivolux AB (Uppsala, Sweden).
“If the study proves successful it will represent a great step forward, mainly for all cancer patients but also for the Swedish drug industry,” says Professor Linder.
The Latest on: Cancer therapies
- King Charles to Resume Public Duties Amid Cancer Battleon April 27, 2024 at 3:51 am
King Charles III is set to make a gradual return to public life after a three-month hiatus following his cancer diagnosis. Buckingham Palace has announced that the 75-year-old monarch will resume his ...
- News Wrap: King Charles returning to public duties after 3-months of cancer treatmenton April 26, 2024 at 3:55 pm
In our news wrap Friday, Britain's King Charles will return to public duties after a three-month break for cancer treatment, Egypt sent a high-level delegation to Israel hoping to revive talks for a ...
- Britain’s King Charles III will resume public duties next week after cancer treatment, palace sayson April 26, 2024 at 3:39 pm
Buckingham Palace says King Charles III will resume his public duties next week following treatment for cancer.
- King Charles - live: Palace shares news on monarch’s cancer treatment as he sets return date for public dutieson April 26, 2024 at 2:17 pm
Palace shares news on monarch’s cancer treatment as he sets return date for public duties - Doctors ‘sufficiently pleased with progress so far’ to allow 75-year-old to step up work again ...
- How King Charles and Kate have supported each other through cancer treatmenton April 26, 2024 at 1:41 pm
As both undergo their respective cancer treatments, the two senior royals have also turned to each other for support. Charles is said to have driven to Windsor Castle to have lunch with Kate just one ...
- King Charles: What kind of cancer treatment is available to him - and what impact could it haveon April 26, 2024 at 11:30 am
The palace has said the King does not have prostate cancer and it is not yet clear what kind of cancer the King is suffering from or what kind of treatment he is having. However, there are three main ...
- King Charles III to return to public duties as he continues cancer treatmenton April 26, 2024 at 11:17 am
King Charles III is returning to his public royal duties as the British monarch continues his recovery from cancer treatment.
- King Charles III to return to public duties amid ongoing cancer treatmenton April 26, 2024 at 10:58 am
King Charles will resume engaging in public duties next week after nearly three months due to a cancer diagnosis.
- King Charles III to return to public duties amid cancer treatmenton April 26, 2024 at 10:46 am
King Charles III will return to public duties next week, a first since his cancer diagnosis was revealed publicly in February. Buckingham Palace announced Friday that Charles, 75, and his wife Queen ...
- King Charles announces return to public royal duties following his cancer treatment. Here's what to know about his health journey.on April 26, 2024 at 10:40 am
His Majesty The King will shortly return to public-facing duties after a period of treatment and recuperation following his recent cancer diagnosis. To help mark this milestone, The King and Queen ...
via Bing News
The Latest on: Multiple myeloma
- ‘Key Signs’ of Cytokine Release Syndrome to Knowon April 26, 2024 at 2:01 pm
For patients with lymphoma or multiple myeloma, speaking up about symptoms of cytokine release syndrome can be lifesaving.
- International Myeloma Foundation Holds 15th Annual Gala at the Edison Ballroom in New York City on April 18on April 25, 2024 at 5:45 am
With Over $675,000 Raised, the Gala Benefits the Peter Boyle Research Fund and Celebrates Groundbreaking Myeloma Research, Education, Support, and AdvocacySTUDIO CITY, Calif., April 25, 2024 (GLOBE ...
- Nurse Suggests Questions to Ask Before Carvykti Treatment for Myelomaon April 24, 2024 at 2:00 pm
With Carvykti now approved for pretreated myeloma, there are conversations that patients should have with their providers before treatment, a nurse said.
- Study points to racial and social barriers that block treatment for multiple myelomaon April 23, 2024 at 1:15 pm
A UC Davis Health study reveals persistent racial and social disparities preventing access to autoHCT, a common bone marrow transplant treatment to halt the progression of multiple myeloma.
- Pharmac proposes to fund new blood cancer multiple myeloma drug pomalidomideon April 22, 2024 at 10:00 pm
Overall, more than 800 patients would benefit, Pharmac said.
- NICE recommends Menarini’s Nexpovio combination to treat multiple myelomaon April 22, 2024 at 4:43 am
The National Institute for Health and Care Excellence (NICE) has recommended Menarini Stemline UK’s Nexpovio (selinexor) as part of a combination treatment for multiple myeloma patients who have ...
- NICE backs wider NHS use of multiple myeloma drug Nexpovioon April 22, 2024 at 4:40 am
Nexpovio (selinexor) – which is sold as Xpovio in some markets – is a first-in-class nuclear export XPO1 inhibitor that was approved last year by the MHRA in combination with Velcade Janssen-Cilag’s ...
- NICE recommends Nexpovio for multiple myeloma patients, addressing treatment gapson April 22, 2024 at 4:17 am
In a significant development for the multiple myeloma community, Menarini Stemline UK today welcomed the final draft guidance from the National Institute for Health and Care Excellence (NICE).
- The Myeloma Trial Result I Did Not See Comingon April 17, 2024 at 8:00 am
A new drug called belantamab mafodotin significantly improved survival in relapsed multiple myeloma patients compared to a standard treatment.
- New Agent Shows Early Promise in Triple-Class Refractory Multiple Myelomaon April 17, 2024 at 5:15 am
With linvoseltamab and other bispecific antibodies inducing deep and durable responses, there might finally be a go-to option for multiple myeloma patients resistant to mainstay treatments.
via Bing News